Double-blinded, placebo-controlled, cross-over pilot study on the efficacy of zileuton for canine atopic dermatitis

Authors

  • Dennis W. Crow,

    Corresponding author
    1. Blanche Saunders Dermatology Laboratory, Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida, USA
    Search for more papers by this author
  • Rosanna Marsella,

    1. Blanche Saunders Dermatology Laboratory, Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida, USA
    Search for more papers by this author
  • Constance F. Nicklin

    1. Blanche Saunders Dermatology Laboratory, Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida, USA
    Search for more papers by this author

Dennis W. Crow. *Present address: Animal Dermatology Referral Clinic, 444 Trinity Mills Road, Suite 101, Dallas, TX 75287, USA. Fax: +1 972 248 9005. E-mail:dcrowdvm@yahoo.com

Abstract

Nine dogs meeting the diagnostic criteria for canine atopic dermatitis were enrolled in a double-blind, placebo-controlled, cross-over clinical trial. In this pilot study, zileuton (a 5-lipoxygenase inhibitor) given orally at 2 mg kg−1 three times daily for 4 weeks significantly decreased erythema in dogs with atopic dermatitis but had no effect on pruritus. Zileuton was well tolerated and no adverse clinical signs were noted. However, one dog developed mild alanine aminotransaminase elevation, which resolved within 1 week of discontinuation of therapy. Monitoring of alanine aminotransaminase may be necessary in dogs receiving zileuton. Further studies with larger number of dogs are needed to evaluate the efficacy of zileuton as treatment for canine atopic dermatitis.

Ancillary